<p>Roche's quarterly sales declined 6 per cent as a drop in Covid-19 treatments and diagnostic testing more than offset gains from haemophilia treatment Hemlibra and multiple sclerosis drug Ocrevus.</p>.<p>Third-quarter revenues slipped to 14.74 billion Swiss francs ($14.84 billion), below market expectations.</p>.<p>The group confirmed its guidance for 2022.</p>
<p>Roche's quarterly sales declined 6 per cent as a drop in Covid-19 treatments and diagnostic testing more than offset gains from haemophilia treatment Hemlibra and multiple sclerosis drug Ocrevus.</p>.<p>Third-quarter revenues slipped to 14.74 billion Swiss francs ($14.84 billion), below market expectations.</p>.<p>The group confirmed its guidance for 2022.</p>